Canadian researchers are launching a large, multi-year international study to try to find a way to help the hundreds of thousands of men diagnosed with prostate cancer every year decide whether to opt for potentially life-altering treatments or choose a watch-and-wait approach.The Canadian Cancer Society and the National Cancer Institute of Canada announced the study Thursday, saying it is hoped the START trial – the acronym stands for Surveillance Therapy Against Radical Treatment – will resolve one of the thorniest dilemmas in prostate cancer care.

“It’s answering some questions that we really need some answers to. Does active treatment at the time of diagnosis really make a difference in terms of long-term survival from prostate cancer?” explained Heather Logan, director of cancer control policy with the Canadian Cancer Society.

To read the entire article click here.